New Test for TDP-43 in Blood Samples
Author Information
Author(s): Jiyan An, Lathika Gopalakrishnan, Vanessa Ortega, Justin Saul, Renu Kadali, Robert Bowser
Primary Institution: Barrow Neurological Institute
Hypothesis
Can a new immunoassay accurately quantify TDP-43 levels in human biofluids?
Conclusion
The study developed a sensitive immunoassay that detected lower levels of TDP-43 in ALS patients compared to healthy controls.
Supporting Evidence
- The assay demonstrated a limit of detection of 4 pg/mL and a working range of 4–20,000 pg/mL.
- Full-length TDP-43 levels were significantly lower in ALS patients compared to healthy controls.
- The study validated the immunoassay's reproducibility and precision across multiple samples.
- Immunodepletion experiments confirmed the specificity of the assay for TDP-43.
Takeaway
Researchers created a new test to measure a protein called TDP-43 in blood, which could help understand diseases like ALS. They found that people with ALS have less of this protein in their blood than healthy people.
Methodology
The study used a Meso Scale Discovery platform to develop an electrochemiluminescence immunoassay for TDP-43 detection in plasma and serum samples.
Potential Biases
Potential bias in sample selection and the specificity of antibodies used in the assay.
Limitations
The study's findings need further validation in larger cohorts and may not account for all variables affecting TDP-43 levels.
Participant Demographics
The study included 101 ALS patients and 115 age-matched healthy controls.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI of the mean between 330 and 425 pg/mL for ALS patients; 95% CI of the mean between 4379 and 5512 pg/mL for healthy controls.
Statistical Significance
p=0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website